Rajiv K. K. Pruthi, M.B.B.S.

The purpose of this study is to provide a secure, comprehensive registry of real-world clinical data, the ATHNdataset, to support standardized data collection at ATHN affiliated blood disorder treatment centers for persons living with blood disorders to support clinical outcomes analysis, research, advocacy, and public health reporting for the blood disorders community.

The purpose of this study is to monitor and better understand the health issues of people with bleeding disorders.

The purpose of this study is to assess the safety of various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD.

The purpose of this study is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia.

This trial is conducted in Europe and the United States of America. The aim of this trial is to compare the pharmacokinetics (the exposure of the trial drug in the body) of nonacog beta pegol (N9-GP) and ALPROLIX® in patients with haemophilia B.

The purpose of this study is to observe participants with hemophilia A and B who have and have not undergone liver transplantation. Participants will be asked to complete health related quality of life questionnaires and provide medical history.

The purpose of this study is to evaluate the safety of SEVENFACT® when used to treat bleeding events in participants with Hemophilia A or B with inhibitors either with or without prophylactic treatment.

The primary objectives of this study are to obtain serological bone turnover markers and bone mineral density (BMD) measurements from hemophilia A and von Willebrand disease (VWD) patients aged  ≥ 6 to ≤ 25 years, to compare BMD measurements by HRpQCT and DXA with respect to severity of hemophilia A (mild, moderate, severe) and vWD, annualized bleeding rates, activity and joint scores, and to identify multivariate predictors (correlates) of BMD measurements, including serological bone turnover markers, biochemical and hormonal markers, chronological age, Tanner stage, gender, height, weight, BMI, type of bleeding disorder, severity of bleeding disorder, history of inhibitors, and joint bleeds.

The purpose of this study is to develop consensus guidelines and establish baseline outcomes data for various clinical complications and procedural events requiring treatment in the population of patients.

The purpose of this study is to compare recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to minimize menorrhagia in women with Type 1 Von Willebrand disease.

The purpose of this study is to determine if people with type 1 VWD experience age related increases in VWF levels and what effect this has on bleeding in this population. In order to discover this, the study will examine medical history, blood and genetic tests for VWD and bleeding and collect information about bleeds from the subjects.

The purpose of this study is to determine the percentage of subjects with confirmed inhibitors (per CDC laboratory criteria; >0.5 Nijmegen Bethesda Units for hemophilia A and >0.3 Nijmegen Bethesda Units for hemophilia B within the first 50 Exposure Days (ED).